Case report
Open access
Aug 2026
Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation
Mutations in ABCC8 and KCNJ11 are associated with the most severe and diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are commonly used off-label as second-line treatment. While octreotide and lanreotide are the most established options, pasireotide—a second-generation somatostatin...
Calvin Kurz, Marcia Roeper, L. Friesl et al.
· Frontiers in Endocrinology · 1 citation